A prospective trial to evaluate the efficacy and tolerability of asunaprevir/daclatasvir combination therapy in cirrhotic patients with hepatitis C virus genotype 1b infection

Trial Profile

A prospective trial to evaluate the efficacy and tolerability of asunaprevir/daclatasvir combination therapy in cirrhotic patients with hepatitis C virus genotype 1b infection

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Mar 2016

At a glance

  • Drugs Asunaprevir/daclatasvir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 14 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top